Research library / Sleep

Long-term chamomile (Matricaria chamomilla L.) treatment for generalized anxiety disorder: A randomized clinical trial

JJ Mao, SX Xie, JR Keefe, I Soeller, QS Li, JD Amsterdam. Phytomedicine. 2016.

Published 2026-10-15Sources checked 2026-10-151 sourceEverstack research teamHow we work

In plain language

After 12 weeks of open-label chamomile, relapse was 15.2% on continued chamomile versus 25.5% on placebo, not significant for the primary outcome; symptoms stayed lower on chamomile.

Limits

Primary outcome missed; disorder population; extract dose, not isolated apigenin.

Source

doi.org/10.1016/j.phymed.2016.10.012 · PubMed 27912875

Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack.